PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933309
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933309
The global molecular imaging market is witnessing consistent growth driven by rising prevalence of chronic diseases and increasing adoption of advanced diagnostic technologies. In 2025, the market was valued at USD 2.32 billion and is projected to grow to USD 2.45 billion in 2026. Over the forecast period, the market is expected to reach USD 3.92 billion by 2034, expanding at a CAGR of 6.05%. North America dominated the market with a 43.69% share in 2025, supported by high healthcare expenditure and early adoption of advanced imaging systems.
Molecular imaging enables visualization and measurement of biological processes at the cellular and molecular levels, playing a crucial role in early disease detection, diagnosis, and treatment monitoring. Technologies such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) are widely used across oncology, neurology, cardiology, and orthopedics.
Market Drivers
The primary driver of the molecular imaging market is the increasing prevalence of chronic and acute disorders, including cancer, Alzheimer's disease, cardiovascular diseases, and neurological conditions. According to the National Cancer Institute, nearly 2.0 million new cancer cases were expected to be diagnosed in the U.S., significantly increasing demand for advanced diagnostic imaging.
Additionally, the growing geriatric population is contributing to higher diagnosis rates. Aging populations are more susceptible to chronic conditions, thereby boosting the utilization of molecular imaging techniques. Rising awareness about early disease detection and continuous improvements in imaging accuracy further support market growth.
Market Restraints and Challenges
Despite steady growth, the market faces challenges due to the high cost of molecular imaging equipment. PET/CT scanners can cost between USD 0.5 million and USD 5.0 million, limiting adoption, particularly in low- and middle-income countries.
Another major challenge is the emergence of a regulated market for refurbished imaging devices. Refurbished PET/CT scanners, priced significantly lower than new systems, are gaining traction in emerging economies. This price gap is restraining new equipment sales and impacting revenue growth for manufacturers.
Market Opportunities and Trends
The expanding range of medical applications for molecular imaging presents strong growth opportunities. Molecular imaging is increasingly used to assess treatment response, guide personalized medicine, and enable point-of-care testing. Faster imaging procedures and improved image quality have further enhanced clinical adoption.
A prominent trend in the market is the shift toward technologically advanced hybrid imaging systems, such as PET/CT and SPECT/CT. These systems offer superior resolution, reduced scan times, and enhanced diagnostic accuracy. Regulatory approvals and continuous innovation by leading manufacturers are accelerating the transition from conventional to hybrid imaging technologies.
By type, Positron Emission Tomography (PET) held the largest market share, driven by rising neurological disorder prevalence and increasing installed scanner bases per million population. The SPECT segment is also expected to grow steadily due to rising R&D investments.
By application, oncology dominated the market, owing to increasing cancer diagnosis rates. Orthopedics and neurology are anticipated to grow at notable CAGRs due to rising injury rates and neurological disorders.
By end-user, diagnostic imaging centers are expected to grow rapidly, supported by patient convenience, reduced waiting times, and the growing number of independent imaging facilities.
Regional Analysis
North America generated USD 1.01 billion in revenue in 2025, driven by advanced healthcare infrastructure and favorable reimbursement policies. Europe continues to grow due to increasing installed imaging bases and government-backed research initiatives. Asia Pacific is projected to be the fastest-growing region, supported by a large patient pool, aging population, and expanding healthcare infrastructure in countries such as China, Japan, and India.
Competitive Landscape
The molecular imaging market is consolidated, with key players such as GE Healthcare, Siemens Healthineers AG, and Koninklijke Philips N.V. dominating global market share. These companies focus on innovation, product launches, and strategic collaborations to strengthen their market presence.
Conclusion
The global molecular imaging market is poised for steady growth, expanding from USD 2.32 billion in 2025 to USD 3.92 billion by 2034. Rising prevalence of chronic diseases, increasing adoption of hybrid imaging technologies, and advancements in personalized medicine are key growth drivers. While high equipment costs and refurbished device markets pose challenges, continuous innovation and expanding clinical applications will ensure sustained market expansion throughout the forecast period.
Segmentation By Type
By Application
By End-user
By Geography